# V1 Empirics Check — qwen/qwen3.5-397b-a17b (Variant A)

**Model:** qwen/qwen3.5-397b-a17b
**Variant:** A
**Date:** 2026-03-30T22:19:14.192739

---

\section*{Referee Report}

\textbf{Manuscript:} The Disclosure Cliff: How Reporting Thresholds Censor Pharmaceutical Payment Data \\
\textbf{Journal:} AER: Insights \\
\textbf{Date:} October 26, 2023

\section{1. Idea Fidelity}
The paper deviates significantly from the Original Idea Manifest in three key dimensions. First, the data scope is drastically reduced: the manifest承诺 ed 80M+ records across 9 years (2016--2024) via full API access, but the paper utilizes only 433,131 records across 4 years (2018, 2020, 2022, 2024) due to API retrieval limits. Second, the identification strategy promised a "moving-threshold bunching estimator" validated by cross-year threshold shifts; while attempted, the execution relies on non-random sampling that threatens the validity of density estimation. Third, the manifest explicitly listed a mechanism test linking to Medicare Part D prescribing data via NPI as a core component of the identification strategy; this element is entirely absent from the paper. These deviations move the project from a comprehensive structural analysis of disclosure avoidance to a descriptive analysis of a sampled subset of reported payments.

\section{2. Summary}
This paper investigates whether the CPI-indexed per-transaction reporting threshold in the CMS Open Payments database creates a systematic blind spot in physician-industry financial data. Using bunching estimation on a sample of general payment records from 2018 to 2024, the authors find significant "missing mass" just below the reporting threshold, concentrated primarily in food and beverage payments. The authors argue this indicates strategic sizing of payments by manufacturers to avoid public disclosure, suggesting that current transparency mandates underestimate the frequency of small-scale industry-physician interactions.

\section{3. Essential Points}
The following issues are critical and must be addressed for the paper to be scientifically valid.

\begin{enumerate}
    \item \textbf{Data Sampling and Density Estimation Validity:} The empirical strategy relies on estimating the density of payment amounts to identify discontinuities. However, the data section states records were retrieved using ``the first 320 pages of 500 records each'' via the API. CMS Open Payments API results are typically sorted by date or transaction ID, not randomly. If the underlying database is sorted by amount (or any variable correlated with amount), this sample is truncated or biased, rendering the density estimation invalid. For a bunching paper, the sample must be representative of the underlying distribution within the bandwidth. \textit{Action Required:} The authors must demonstrate that the API retrieval method yields a random sample with respect to payment amount, or they must obtain the full downloadable datasets (available as CSVs on data.cms.gov) rather than relying on paginated API queries.

    \item \textbf{Identification Logic and Observability:} The core identification strategy conflates ``avoidance'' with ``reporting rules.'' The paper argues that ``missing mass'' below the threshold in the \textit{observed} data indicates avoidance. However, payments below the threshold are only observed if the annual aggregate exceeds ~\$100. Therefore, the observed distribution below the threshold is already selected on the aggregate relationship intensity. A smooth counterfactual fitted to the observed data cannot distinguish between (a) manufacturers avoiding the threshold to stay hidden, and (b) manufacturers simply having fewer small transactions among those who exceed the aggregate threshold. Without an external measure of total transactions (reported + unreported), the bunching estimator measures selection into reporting, not necessarily strategic avoidance. \textit{Action Required:} The authors need to formally model the selection process or restore the promised Part D mechanism test to show that physicians with ``missing'' payments exhibit prescribing changes
